A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Inclusion Criteria: * Histologically documented diagnosis of DLBCL. * Phase 1: any DLBCL subtype. * Phase 2: activated B-cell or unclassifiable subtypes confirmed by immunohistochemistry using the Hans algorithm * Relapsed or refractory DLBCL, defined as having received at least 1 but no more than 3 prior treatment regimens and ineligible for high-dose chemotherapy/autologous stem cell transplant. * Fluorodeoxyglucose-avid disease (based on local evaluation) per the Lugano Classification. Fluorodeoxyglucose-avid disease is defined as disease with a 5-point scale score of 4 or 5. * Archived tumor tissue (block or 15-20 unstained slides) available, or be willing to undergo an incisional or excisional lymph node biopsy of accessible adenopathy (or, in less accessible lymph nodes, 4 to 8 core biopsies). * At least 1 measurable (≥ 2 cm in longest dimension) lesion on CT scan or magnetic resonance imaging (MRI). * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2. Exclusion Criteria: * Transformed DLBCL or DLBCL with coexistent histologies (eg, follicular or mucosa-associated lymphoid tissue lymphoma). * Primary mediastinal (thymic) large B-cell lymphoma. * Known central nervous system lymphoma (either primary or metastatic). * Allogeneic stem cell transplant within the previous 6 months, or active graft versus host disease following allogeneic transplant. * Use of immunosuppressive therapy within 28 days of starting study treatment. Immunosuppressive ther…